Results 21 to 30 of about 43,410 (236)

The safety of attenuated and recombinant nasal influenza vaccines in terms of the development of secondary bacterial superinfection

open access: yesЖурнал микробиологии, эпидемиологии и иммунобиологии, 2019
Introduction. Influenza is a severe viral disease. The most common post-influenza complication is pneumonia. Earlier, we developed an experimental mouse model of viralbacterial pneumonia induced by successive infection with influenza virus and St. aureus,
N. R. Makhmudova   +6 more
doaj   +1 more source

Superior neutralizing antibody response and protection in mice vaccinated with heterologous DNA prime and virus like particle boost against HPAI H5N1 virus. [PDF]

open access: yesPLoS ONE, 2011
BACKGROUND: Although DNA plasmid and virus-like particle (VLP) vaccines have been individually tested against highly pathogenic avian influenza (HPAI) H5N1 viruses, the combination of both vaccines into a heterologous prime-boost strategy against HPAI ...
Heng Ding   +6 more
doaj   +1 more source

Dry Formulation of Virus-Like Particles in Electrospun Nanofibers

open access: yesVaccines, 2021
Biologics can be combined with liquid polymer materials and electrospun to produce a dry nanofibrous scaffold. Unlike spray-drying and freeze-drying, electrospinning minimizes the physiological stress on sensitive materials, and nanofiber mat properties ...
Sasheen Dowlath   +6 more
doaj   +1 more source

Impedance-compensated grid synchronisation for extending the stability range of weak grids with voltage source converters [PDF]

open access: yes, 2016
This paper demonstrates how the range of stable power transfer in weak grids with voltage source converters (VSCs) can be extended by modifying the grid synchronisation mechanism of a conventional synchronous reference frame phase locked loop (PLL).
D'Arco, Salvatore   +3 more
core   +2 more sources

Enhanced Immunogenicity of an Influenza Ectodomain Matrix-2 Protein Virus-like Particle (M2e VLP) Using Polymeric Microparticles for Vaccine Delivery

open access: yesViruses, 2022
In this study, we demonstrate how encapsulating a conserved influenza ectodomain matrix-2 protein virus-like particle (M2e5x VLP) into a pre-crosslinked bovine serum albumin (BSA) polymeric matrix enhances in vitro antigen immunogenicity and in vivo ...
Keegan Braz Gomes   +5 more
doaj   +1 more source

Promotion of Cellular and Humoral Immunity against Foot-and-Mouth Disease Virus by Immunization with Virus-Like Particles Encapsulated in Monophosphoryl Lipid A and Liposomes

open access: yesVaccines, 2020
Virus-like particles (VLPs) have emerged as promising vaccine candidates against foot-and-mouth disease (FMD). However, such vaccines provide a relatively low level of protection against FMD virus (FMDV) because of their poor immunogenicity.
Woo Sik Kim   +5 more
doaj   +1 more source

Alterations of membrane curvature during influenza virus budding [PDF]

open access: yes, 2014
Influenza A virus belongs to the Orthomyxoviridae family. It is an enveloped virus that contains a segmented and negative-sense RNA genome. Influenza A viruses cause annual epidemics and occasional major pandemics, are a major cause of morbidity and ...
Agnieszka Martyna   +29 more
core   +1 more source

Pigs Immunized with the Virus-like Particle Vaccine Are Protected against the Hepatitis E-3 Virus

open access: yesVaccines, 2021
In this study, we generated the HEV virus-like particle (VLP) vaccine expressing 239 amino acids (367–605 aa) of the HEV-3 ORF2 using the baculovirus expression system.
Hyeon-Jeong Go   +11 more
doaj   +1 more source

Virus-Like Particles and Nanoparticles for Vaccine Development against HCMV

open access: yesViruses, 2019
Human cytomegalovirus (HCMV) infects more than 70% of the human population worldwide. HCMV is responsible for high morbidity and mortality in immunocompromised patients and remains the leading viral cause of congenital birth defects. Despite considerable
Michela Perotti, Laurent Perez
doaj   +1 more source

Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine

open access: yesiScience
Summary: Continuing emergence of variants of concern resulting in reduced SARS-CoV-2 vaccine efficacy necessitates additional prevention strategies. The structure of VLPCOV-01, a lipid nanoparticle-encapsulated, self-amplifying RNA COVID-19 vaccine with ...
Masayuki Aboshi   +14 more
doaj   +1 more source

Home - About - Disclaimer - Privacy